NTT-DOCOMO
17.1.2024 01:11:28 CET | Business Wire | Press release
NTT DOCOMO, INC. announced today that it will unveil a number of world-first technologies among a total of 31 innovative technologies for 5G Evolution, 6G, Generative AI and more during docomo Open House'24, an exhibition of cutting-edge technological advancements to be held in Tokyo on January 17 and 18.
A dedicated website (https://docomo-openhouse24.smktg.jp/public/application/add/32) will be accessible from January 17 until February 29 to showcase the exhibits, including highlights such as the following.
5G Evolution & 6G
Sub-terahertz bandwidth for ultra-high-capacity communication over 100Gbps
Cutting-edge technologies such as extreme-high-speed transmissions over 100Gbps, together with AI, will be deployed to meet the advanced requirements of 6G in the coming future. As one example, DOCOMO will launch new communication infrastructure to harness sub-terahertz bandwidths for the integration of physical space and cyberspace.
https://docomo-openhouse24.smktg.jp/public/session/view/97
FEEL TECH® for sharing sensory perceptions via human-augmentation platform
FEEL TECH® is the world's first technology for sharing taste sensations between individuals via DOCOMO's human-augmentation mobile platform. It is expected to be used in the metaverse, as well as in movies and animations, to incorporate taste expressions into extra-rich content that people will experience with an immersive sense of presence.
https://www.docomo.ne.jp/english/info/media_center/pr/2023/1221_00.html
https://docomo-openhouse24.smktg.jp/public/session/view/76
Network technology for non-terrestrial areas, including air, sea and space
In the future, networks incorporating high-altitude platform stations (HAPS) will support disaster communications, ship and drone connectivity, and communications in mountainous and remote areas. The exhibit will showcase the latest technologies for non-terrestrial network (NTN) HAPS and underwater drones for mobile coverage beyond the reach of conventional terrestrial network areas, from remote seas to low-orbit space.
https://www.docomo.ne.jp/english/info/media_center/pr/2023/1207_00.html
https://docomo-openhouse24.smktg.jp/public/session/view/101
Next-generation cloud slicing and 5GC on AWS to meet specific network needs
Tailoring networks to meet specific quality-of-service requirements remains a challenge. This innovative solution combines end-to-end orchestration, QoS visualization and monitoring, and 5G Core from AWS to deliver flexible network quality for specific locations and time scenarios. By integrating the cloud, energy efficiency and on-demand network quality, the solution will help realize highly sustainable networks.
https://docomo-openhouse24.smktg.jp/public/session/view/69
5G application to address diverse mobile needs in industrial settings
The adoption of 5G in the industrial sector is still limited. More extensive 5G implementation in the industrial world will require comprehensive analysis and multi-dimensional verification that can address diverse mobile needs and environments. DOCOMO has developed an advanced yet portable simulator that makes it easy to visualize 5G wireless transmission characteristics and electromagnetic interference effects in each customer's unique industrial setting.
https://docomo-openhouse24.smktg.jp/public/session/view/107
Generative AI
Enlivening the metaverse with generative AI that creates non-player characters
The world-first technology from DOCOMO uses generative AI to create non-player characters in the metaverse. The innovative technology, which automatically generates each character's appearance, behavior and role to eliminate the need for experts with specialized know-how, will help realize more enriched metaverse experiences in the future.
https://www.docomo.ne.jp/english/info/media_center/pr/2024/0116_01.html
https://docomo-openhouse24.smktg.jp/public/session/view/67
DOCOMO will also showcase a selection of the above technologies at MWC Barcelona 2024 from February 26 to 29.
https://www.docomo.ne.jp/english/info/media_center/pr/2024/0116_00.html
Permission granted for the use of copyrighted images.
About NTT DOCOMO
NTT DOCOMO, Japan's leading mobile operator with over 88 million subscriptions, is one of the world's foremost contributors to 3G, 4G and 5G mobile network technologies. Beyond core communications services, DOCOMO is challenging new frontiers in collaboration with a growing number of entities ("+d" partners), creating exciting and convenient value-added services that change the way people live and work. Under a medium-term plan toward 2020 and beyond, DOCOMO is pioneering a leading-edge 5G network to facilitate innovative services that will amaze and inspire customers beyond their expectations.
https://www.docomo.ne.jp/english/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240116271722/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 01:35:00 CEST | Press release
~ Creating Climate Solutions and New Market Opportunities through Source-Specific CO2 Emission and Uptake Monitoring via Satellite Constellation and Aircraft ~ Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Cap
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom